In this issue:
TNF inhibitors and serious infection risk in paediatric IBD
Vedolizumab concentrations and clinical outcomes in IBD
Infliximab induction in steroid-refractory acute severe colitis
Proactive vs. reactive adalimumab concentration monitoring in paediatric CD
Ustekinumab and histological disease activity in CD
CDEC + PEN induces sustained remission in mild/moderate paediatric CD
Mortality associated with SCC development in thiopurine-treated IBD
TNF inhibitor + immunomodulator combination and IBD complications
Vedolizumab ineffective for PSC in IBD
Cost-effectiveness of ileocaecal resection vs. infliximab for terminal ileitis in CD
Please login below to download this issue (PDF)